A detailed history of Goldman Sachs Group Inc transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 321,359 shares of CABA stock, worth $880,523. This represents 0.0% of its overall portfolio holdings.

Number of Shares
321,359
Previous 395,823 18.81%
Holding current value
$880,523
Previous $2.96 Million 48.78%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.94 - $8.24 $293,388 - $613,583
-74,464 Reduced 18.81%
321,359 $1.52 Million
Q2 2024

Aug 13, 2024

SELL
$7.22 - $18.82 $211,914 - $552,385
-29,351 Reduced 6.9%
395,823 $2.96 Million
Q1 2024

May 15, 2024

BUY
$16.79 - $25.38 $3.14 Million - $4.75 Million
187,037 Added 78.54%
425,174 $7.25 Million
Q4 2023

Feb 13, 2024

SELL
$12.21 - $23.36 $755,982 - $1.45 Million
-61,915 Reduced 20.63%
238,137 $5.41 Million
Q3 2023

May 14, 2024

BUY
$11.84 - $18.65 $733,073 - $1.15 Million
61,915 Added 26.0%
300,052 $4.57 Million
Q3 2023

Nov 14, 2023

BUY
$11.84 - $18.65 $3.55 Million - $5.6 Million
300,052 New
300,052 $4.57 Million
Q1 2023

May 14, 2024

BUY
$7.08 - $12.62 $1.07 Million - $1.9 Million
150,600 Added 1369.59%
161,596 $1.34 Million
Q1 2023

May 11, 2023

BUY
$7.08 - $12.62 $1.14 Million - $2.04 Million
161,596 New
161,596 $1.34 Million
Q3 2022

May 14, 2024

SELL
$0.63 - $2.05 $1,857 - $6,045
-2,949 Reduced 21.15%
10,996 $7,000
Q3 2022

Nov 10, 2022

SELL
$0.63 - $2.05 $1,857 - $6,045
-2,949 Reduced 21.15%
10,996 $0
Q2 2022

May 14, 2024

SELL
$0.99 - $2.11 $221,950 - $473,045
-224,192 Reduced 94.14%
13,945 $15,000
Q2 2022

Aug 15, 2022

BUY
$0.99 - $2.11 $85 - $181
86 Added 0.62%
13,945 $15,000
Q1 2022

May 16, 2022

BUY
$1.68 - $3.92 $1,150 - $2,685
685 Added 5.2%
13,859 $28,000
Q4 2021

Feb 14, 2022

SELL
$3.36 - $14.64 $100,104 - $436,169
-29,793 Reduced 69.34%
13,174 $50,000
Q3 2021

Nov 10, 2021

BUY
$7.0 - $12.5 $300,769 - $537,087
42,967 New
42,967 $522,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $79.5M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.